ClinEvident™ · by Scientari
Clinical evidence, graded.
For the decisions around your molecule.
Independent grades of the published human evidence on drugs, supplements and behaviors, including what patients take alongside your drug: what helps, what harms, and what was tested and did nothing. Every grade links to published research. No one can pay for a grade, or to change one.
Built for pharma and biotech teams
Four teams, four questions, one graded evidence base. The null and harm results are often the most useful, and the hardest to find in one place.
Medical Affairs
Graded, citable answers when doctors ask about supplements with your drug.
Clinical development
Which supplements could confound a trial, and which extra arms are worth running.
Market access & HEOR
Evidence kept separate by molecule and preparation, head-to-head results included.
BD, lifecycle & safety
Combination opportunities, and populations the trials left out.
The Rx–Supplement Evidence Divide
No supplement in our registry scores above C+. The highest-evidence healthspan interventions are repurposed prescription drugs. This isn't bias — it's what the published data shows.
Empagliflozin (SGLT2i)
SGLT2 inhibitors (empagliflozin, dapagliflozin) are the highest-evidence longevity compound class in the registry, with A+ grades for both CKD and heart failure indications. The…
Semaglutide
Semaglutide carries some of the strongest human outcome evidence in the ClinEvident registry. Originally approved for type 2 diabetes (Ozempic) and obesity (Wegovy), it has demonstrated…
Metformin
Metformin has extensive observational evidence suggesting longevity benefits, including the landmark UKPDS study showing reduced all-cause mortality in diabetic patients. A 2024 Nature…
Omega-3 (high-dose EPA / icosapent ethyl, prescription)
Prescription high-dose purified EPA. One large trial (REDUCE-IT) showed a 25% reduction in cardiovascular events, and it is FDA-approved (2019). BUT the size of that benefit is contested…
Grade and summary pending reviewUrolithin A (Mitopure)
Urolithin A is the cleanest evidence story in the supplement space. Timeline/Amazentis has published six human clinical trials showing improved mitochondrial function and muscle endurance.…
Colchicine
An anti-inflammatory drug with two large trials showing it lowers the risk of heart attacks and strokes in people who already have cardiovascular disease. FDA-approved in 2023 for that use.…
Grade and summary pending reviewAcarbose
A diabetes drug with a large, high-quality trial. It did NOT reduce heart attacks or deaths, but it did reduce progression to diabetes by about 18% in people with prediabetes. Its longevity…
Grade and summary pending reviewTestosterone replacement therapy (TRT)
For men with DIAGNOSED hypogonadism (clinically low testosterone), a large safety trial (TRAVERSE) found it does not raise major cardiac events, though it carries some real risks. There is…
Grade and summary pending reviewCoQ10 (Ubiquinol)
CoQ10 has the longest clinical evidence history of any longevity supplement. A 2024 meta-analysis found CoQ10 supplementation significantly reduced major adverse cardiovascular events. The…
Rapamycin (Sirolimus)
Rapamycin has the strongest preclinical lifespan extension data of any compound — consistent results across yeast, worms, flies, and mice, including the ITP (Interventions Testing…
Vitamin D
One of the most rigorously tested supplements in existence. For people who already have adequate levels, the large trials (VITAL, ViDA, D-Health) show it does NOT prevent cancer,…
Grade and summary pending reviewNattokinase
A fibrinolytic enzyme from fermented soy, studied in human trials for effects on clotting markers, with one study using an imaging endpoint. There is a dose gap worth knowing about: trials…
Grade and summary pending reviewHow We Grade Evidence
Every intervention is scored across six dimensions of the Evidence Grading Framework (EGF), published as the ClinEvident Evidence Grading Standard. The methodology is published. The grades are transparent. The data speaks.
Human Outcome Weight
Does it change hard clinical endpoints in humans? RCTs with mortality, morbidity, or functional outcomes score highest.
Biomarker Relevance
Are the biomarkers it moves actually predictive of aging or disease? Validated surrogate endpoints vs. exploratory markers.
Signal Source Quality
Where does the evidence come from? Peer-reviewed RCTs in NEJM vs. open-label pilot studies vs. press releases.
Organ Specificity
How precisely does the evidence map to specific organ systems? Targeted organ data vs. whole-organism generalities.
Interaction Certainty
How well-characterized are the interactions with other compounds? Graded at the compound-pair level.
Translational Maturity
How close is the evidence to clinical actionability? Phase 3 complete vs. animal-only vs. in-vitro.
Working on an asset?
Tell us the molecule and the decision you’re facing. We’ll tell you what the published evidence can and can’t answer.
Browsing for yourself? Grades are free to see, and a free account adds study-level detail. Create a free account or see plans.